Bank of America
NTGN

Bank of America’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Bank of America’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,849
Closed -$41K – 7370
2020
Q1 		$41K Sell
15,849
-12,988
-45% -$21.3K ﹤0.01% 5947
2019
Q4 		$34K Sell
28,837
-4,998
-15% -$7.99K ﹤0.01% 6375
2019
Q3 		$58K Sell
33,835
-9,502
-22% -$28.9K ﹤0.01% 6262
2019
Q2 		$206K Buy
43,337
+8,919
+26% +$49.9K ﹤0.01% 5620
2019
Q1 		$222K Buy
34,418
+12,706
+59% +$66.5K ﹤0.01% 5473
2018
Q4 		$109K Buy
21,712
+6,493
+43% +$45.4K ﹤0.01% 5867
2018
Q3 		$130K Buy
15,219
+14,150
+1,324% +$157K ﹤0.01% 5747
2018
Q2 		$13K Buy
+1,069
New +$14.6K ﹤0.01% 6612

Bank of America's NTGN Position: Q2 2020 in Review

Bank of America sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 15,849 shares — an estimated $41K sold.

Bank of America first reported a position in NTGN in Q2 2018 and held it in 8 quarters. The position peaked at $222K in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

  • Bank of America reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Bank of America sold 15,849 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $41K.
  • Bank of America first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
  • Bank of America's Neon Therapeutics, Inc. Common Stock position peaked at $222K in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Bank of America's 13F filing for Q2 2020, filed 14 Aug 2020.